Alliance A092204

Who Can Participate in the Study?

Age Group
Adults

Study Details

Full Title
Protocol A092204, A Phase II Study of Cabozantinib in Combination with Cemiplimab (REGN2819) (Cabo-Cemiplimab (REGN2810)) Versus Cabozantinib Alone in Adolescents and Adults with Advanced Adrenocortical Cancer (NCT06900595)
Principal Investigator
Headshot of Diane L. Reidy-Lagunes
Professor of Medicine
Protocol Number
IRB: PRO00119543
NCT: NCT06900595
Phase
Phase II
ClinicalTrials.gov
Enrollment Status
OPEN TO ACCRUAL
Participate